Yurpeak 15mg KwikPen
Description
Yurpeak 15mg KwikPen is a prescription injectable medication containing Tirzepatide 15mg as its active ingredient. It belongs to a class of medicines known as dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists. It is designed for once-weekly subcutaneous administration and is used in the management of type 2 diabetes and chronic weight management in eligible adults.
The KwikPen is a prefilled, multi-dose injection device designed to deliver four fixed weekly doses. Yurpeak is available in different strengths, with 15mg representing the highest available strength.
Composition and Product Specifications
Brand Name: Yurpeak
Active Ingredient: Tirzepatide
Strength: 15mg per 0.6ml dose
Dosage Form: Solution for injection
Device: Multi-dose prefilled KwikPen
Total Pen Content: 60mg in 2.4ml
Number of Doses: Four weekly doses
Route of Administration: Subcutaneous injection
Administration Frequency: Once weekly
The formulation also contains inactive ingredients, including benzyl alcohol, glycerol, phenol, sodium chloride and phosphate buffer components.
Therapeutic Uses of Yurpeak 15mg
Tirzepatide is used as an adjunct to diet and exercise for managing type 2 diabetes mellitus in adults whose blood glucose levels require additional control.
It is also indicated for chronic weight management in adults with obesity (BMI of 30 kg/m² or above), or overweight (BMI of 27 kg/m² or above) with at least one weight-related health condition.
Yurpeak works by activating GIP and GLP-1 receptors, which are involved in glucose regulation, insulin secretion, appetite and food intake. Its effects include improving glucose-dependent insulin secretion, regulating appetite and supporting weight reduction when combined with appropriate lifestyle measures.
Dosage and Administration
Yurpeak 15mg KwikPen is generally used as a maintenance-strength option following gradual dose escalation under medical supervision. Treatment typically begins with 2.5mg once weekly for four weeks, followed by 5mg once weekly. Further increases of 2.5mg may be considered at intervals of at least four weeks, depending on treatment response and tolerability.
The 15mg dose should only be used when prescribed by a qualified healthcare professional. It is administered under the skin of the abdomen, thigh or upper arm. Injection sites should be rotated regularly.
Patients should follow the official instructions supplied with the KwikPen and should never share their pen with another person.
Possible Side Effects and Safety Precautions
Commonly reported adverse reactions associated with tirzepatide include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These gastrointestinal symptoms may occur more frequently during dose escalation.
Additional precautions include monitoring for dehydration, low blood glucose, particularly when used with insulin or sulfonylureas, and symptoms of pancreatitis. Patients should inform their healthcare professional about existing medical conditions and other medicines before starting treatment.
Yurpeak is a prescription medication and should be used only under appropriate medical supervision. It is not intended for self-medication.
Storage Information
Store unused KwikPens in a refrigerator at 2°C–8°C.
Do not freeze the medication.
After first use, store at room temperature up to 30°C.
Use the opened pen within 30 days.
Protect the pen from excessive heat and keep it away from children.
Frequently Asked Questions
1. What is Yurpeak 15mg KwikPen used for?
It is used for the management of type 2 diabetes and chronic weight management in eligible adults, alongside appropriate diet and exercise.
2. What is the active ingredient in Yurpeak 15mg?
The active pharmaceutical ingredient is Tirzepatide, a dual GIP and GLP-1 receptor agonist.
3. How many doses does one Yurpeak 15mg KwikPen contain?
One prefilled pen contains four fixed doses of 15mg, administered once weekly.
4. Is Yurpeak 15mg suitable for everyone?
No. Suitability depends on individual medical history, treatment requirements and professional assessment. It should only be used with a valid prescription.
5. How should Yurpeak 15mg KwikPen be stored?
Unused pens should be refrigerated at 2°C–8°C and must not be frozen. After first use, the pen can be stored at temperatures up to 30°C for a maximum of 30 days.